Are Bacteria a Secret Weapon Against Eczema?

NIH study suggests a potentially cheap and effective treatment for a painful condition.

Inflammation, itching, painful skin lesions: This is everyday life for patients with atopic dermatitis, a type of eczema that affects roughly 11 percent of adults and 7 percent of children in the United States and accounts for nearly $5.3 billion in annual health care costs. Topical steroids, usually hydrocortisone ointments, are often the first line of defense against eczema. The list price for a jar of such ointment can exceed $100—and it usually needs to be applied daily.

“Living with atopic dermatitis can be physically and emotionally challenging,” Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, said in a statement. “Currently available therapies can be time-consuming—requiring multiple daily applications—and costly.”

Indeed, skincare companies target eczema patients with expensive lotions, oils, and other products. Even within the health care industry, a 2017 study found, outpatient care and prescription costs add up to thousands of dollars each year for patients with atopic dermatitis.

Now, scientists have identified a potentially cheap and effective alternative: bacteria.

In an early-phase clinical trial at the National Institutes of Health, the bacterium Roseomonas mucosa reduced the severity of atopic dermatitis in adults and children. The bug, naturally present on human skin, was previously shown to improve symptoms in mice. The ongoing trial is the first time it has shown results in human patients.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    SkinBiotherapeutics Plc

    More articles like this

    SkinBiotherapeutics Plc

    SkinBioTherapeutics plc involved in new research grant

    SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, announced today its collaboration as industrial partner in a grant awarded by the Biotechnology and Biological Sciences Research Council (BBSRC) to The University of Manchester. The

    SkinBiotherapeutics Plc

    Skinbiotherapeutics files new patent application

    SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, announced today a new patent filing. The patent application is to cover the use of SkinBiotix® for increasing filaggrin levels in skin. Filaggrin is a protein

    SkinBiotherapeutics Plc

    Skinbiotherapeutics PLC Plans for Human Study

    SkinBioTherapeutics plc (LON:SBTX), a life science company focused on skin health, has today provided the following update: Human study The design of the human study planned for Q3 2018 has now been finalised. This will be conducted

    SkinBiotherapeutics Plc

    Gateway to the Mind

    The microbiome is the strange invisible world of our non human selves. On and in all of us are hoards of microbes. Their impact on our physical health is becoming clear to science, but a controversial

    SkinBiotherapeutics Plc

    INTERVIEW: SkinBiotherapeutics Skinbiotix Positive Results in Cream

    SkinBioTherapeutics Plc (LON:SBTX) CEO Dr. Cath O’Neill talks to DirectorsTalk about the positive results skinbiotix shows in cream formulation. Cath explains the results, the significance, how the technology works, stability testing, the next major milestones and

    SkinBiotherapeutics Plc

    Pro- and prebiotics on the skin?

    An interview with Cath O’Neill by Kristin Neumann, MyMicrobiome Cath is coming from the skin research area, being an expert on skin health. During the last years her research focussed on the skins microbiome. With her company